Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients

27 May 2022

Abstract excerpt

Sotrovimab is a monoclonal antibody used as monotherapy in outpatients at risk of developing severe COVID-19 disease. Indications include patients with respiratory, cardiac, metabolic, and immunosuppression comorbidities. Rockett and colleagues1 have shown that, among 100 patients infected with the delta (B.1.617.2) variant and treated with sotrovimab monotherapy, four were immunocompromised and rapidly developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35636438
DOI: 10.1016/s2666-5247(22)00120-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patientsPMID 35636438Read ↗

Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patientsSemantic proximity Read ↗

High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variantSemantic proximity Read ↗

Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 VariantsSemantic proximity Read ↗

Longitudinal Analysis of Escape Mutations in SARS-CoV-2 Omicron Variants after Sotrovimab Use in Immunodeficient PatientsSemantic proximity Read ↗

Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab.Semantic proximity Read ↗

Frequent emergence of resistance mutations following complex intra-host genomic dynamics in SARS-CoV-2 patients receiving SotrovimabSemantic proximity Read ↗

Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant.Semantic proximity Read ↗

Potential Benefit of Early Treatment with Sotrovimab in Patients With High Risk for Severe COVID-19 Carrying BA.2 InfectionSemantic proximity Read ↗

Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion.Semantic proximity Read ↗

RESISTANCE CONFERRING MUTATIONS IN SARS-CoV-2 DELTA FOLLOWING SOTROVIMAB INFUSIONSemantic proximity Read ↗

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimabSemantic proximity Read ↗

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineagesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.